利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.031 秒)

    METABOLIC AND CARDIOPROTECTION BY THE MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE
    3.
    发明申请
    METABOLIC AND CARDIOPROTECTION BY THE MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE 有权
    由MYOKINE FOLLISTATIN-LIKE 1 POLYPEPTIDE代谢和保护

    公开(公告)号：US20100227817A1

    公开(公告)日：2010-09-09

    申请号：US12682898

    申请日：2008-10-20

    申请人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    IPC分类号： A61K38/22 ,  A61P9/10 ,  A61P3/08

    CPC分类号： A61K38/1709 ,  Y10S514/824 ,  Y10S514/866

    摘要： Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

    摘要翻译： 本文描述了与发现Follistatin样1蛋白（Fst1-1）在体内具有代谢和心脏保护作用有关的方法和组合物。 Fstl-1及其部分和衍生物或变体可用于治疗或预防代谢疾病或病症，并治疗或预防心脏肌肉供血中断引起的心脏损伤。

    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION
    4.
    发明申请
    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION 审中-公开
    化学和方法来衡量代谢功能和恢复正常代谢功能

    公开(公告)号：US20110274689A1

    公开(公告)日：2011-11-10

    申请号：US13100895

    申请日：2011-05-04

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： A61K38/16 ,  G01N33/53 ,  C12Q1/68 ,  G01N33/566 ,  A61K39/395 ,  A61P3/08

    摘要： The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.

    摘要翻译： 本发明涉及恢复正常代谢功能的治疗，包括但不限于正常的葡萄糖水平。 在一个实施方案中，本发明考虑了通过施用包含至少一部分人Sfrp5的组合来降低具有升高的葡萄糖水平的受试者的升高的葡萄糖水平的方法。 在一个实施方案中，本发明考虑了通过施用包含但不限于抗体抑制剂的Wnt5a抑制剂的组合物降低葡萄糖水平升高的受试者中升高的葡萄糖水平的方法。

    Compounds and Methods to Measure Metabolic Function and Restore Normal Metabolic Function
    5.
    发明申请
    Compounds and Methods to Measure Metabolic Function and Restore Normal Metabolic Function 审中-公开

    公开(公告)号：US20190292256A1

    公开(公告)日：2019-09-26

    申请号：US16259150

    申请日：2019-01-28

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： C07K16/28 ,  C07K16/18 ,  A61K38/17

    摘要： The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.

    METABOLIC REGULATORS AND USES THEREOF
    6.
    发明申请
    METABOLIC REGULATORS AND USES THEREOF 审中-公开
    代谢调节剂及其用途

    公开(公告)号：US20090142336A1

    公开(公告)日：2009-06-04

    申请号：US12280961

    申请日：2007-02-23

    申请人： Kenneth Walsh ,  Noriyuki Ouchi ,  Ling Zeng

    发明人： Kenneth Walsh ,  Noriyuki Ouchi ,  Ling Zeng

    IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/02

    CPC分类号： A61K38/2221 ,  A61K38/1709 ,  A61K38/1825 ,  A61K38/39 ,  A61K38/45 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and/or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSP1 (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;1 110017116Rik; SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO: 18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO: 12); Ins16 (AF_156094; SEQ ID NO: 20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention.

    摘要翻译： 本发明涉及影响代谢功能的代谢调节剂，例如影响肌肉质量的代谢调节剂，肌肉再生，肌肉肥大，脂肪量，胰岛素和葡萄糖敏感性，血管生成和心血管功能。 特别地，本发明涉及通过施用有效量的包含试剂的药物组合物调节代谢功能，其中所述试剂活化或抑制代谢调节剂的活性和/或基因表达。 本发明的代谢调节剂是例如MSP1（2160028F08Rik; SEQ ID NO：16）; MSP2（2310043I08Rik; SEQ ID NO：17）; MSP3（NM_026754; 110017116Rik; SEQ ID NO：1）; MSP4（4732466D17Rik; SEQ ID NO：18）; MSP 5（NM_024237; 1600015H20Rik; SEQ ID NO：12）; Ins16（AF_156094; SEQ ID NO：20）。 本发明还提供筛选影响本发明的代谢调节剂的试剂的方法。

    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION
    7.
    发明申请
    COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION 审中-公开

    公开(公告)号：US20170145091A1

    公开(公告)日：2017-05-25

    申请号：US15267712

    申请日：2016-09-16

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： C07K16/28

    摘要： The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor.

    Method of treating ischemic injury with follistatin-like 1 polypeptide
    8.
    发明授权
    Method of treating ischemic injury with follistatin-like 1 polypeptide 有权
    用卵泡抑素样1多肽治疗缺血性损伤的方法

    公开(公告)号：US08329650B2

    公开(公告)日：2012-12-11

    申请号：US12682898

    申请日：2008-10-20

    申请人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Yuichi Oshima ,  Noriyuki Ouchi

    IPC分类号： A61P9/10 ,  A61P39/06 ,  C07K14/545

    CPC分类号： A61K38/1709 ,  Y10S514/824 ,  Y10S514/866

    摘要： Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

    摘要翻译： 本文描述了与发现Follistatin样1蛋白（Fst1-1）在体内具有代谢和心脏保护作用有关的方法和组合物。 Fstl-1及其部分和衍生物或变体可用于治疗或预防代谢疾病或病症，并治疗或预防心脏肌肉供血中断引起的心脏损伤。

    DIAGNOSTIC USES OF FOLLISTATIN-LIKE 1
    9.
    发明申请
    DIAGNOSTIC USES OF FOLLISTATIN-LIKE 1 审中-公开
    类似药物的诊断用途1

    公开(公告)号：US20090326053A1

    公开(公告)日：2009-12-31

    申请号：US12475175

    申请日：2009-05-29

    申请人： Kenneth Walsh ,  Noriyuki Ouchi ,  Yuichi Oshima

    发明人： Kenneth Walsh ,  Noriyuki Ouchi ,  Yuichi Oshima

    IPC分类号： A61K31/711 ,  C12M1/34 ,  A61P9/10

    CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/4704

    摘要： The present invention generally relates to methods, systems and computer readable media for the diagnosis and/or prognosis of a cardiac stress and/or skeletal muscle stress in a subject. In particular, in one embodiment, the methods, systems and computer readable media detect a level of Fstl expression, such as Fstl1 polypeptide or mRNA expression in a biological sample obtained from a subject, where a high level relative to a reference Fstl expression level is indicative of a subject having, or is at risk of cardiac stress and/or skeletal muscle stress. In such embodiments, the method futher comprises administering or undertaking an appropriate therapy in a subject identified to have or be at risk of cardiac stress and/or skeletal muscle stress. Another aspect of the present invention relates to the methods, systems and computer readable media detect a level of Fstl expression, such as Fstl1 polypeptide or mRNA expression in a biological sample obtained from a subject where a low level relative to a reference Fstl expression level is indicative of a subject having, or is at risk of diabetes and/or metabolic dysfunction. In such embodiments, the method futher comprises administering or undertaking an appropriate therapy in a subject identified to have or be at risk of diabetes and/or metabolic dysfunction.

    摘要翻译： 本发明一般涉及用于诊断和/或预测受试者心脏应激和/或骨骼肌应力的方法，系统和计算机可读介质。 特别地，在一个实施方案中，方法，系统和计算机可读介质检测Fst1表达水平，例如从受试者获得的生物样品中的Fstl1多肽或mRNA表达，其中相对于参考Fst1表达水平的高水平为 指示受试者具有或具有心脏应激和/或骨骼肌应激的风险。 在这样的实施方案中，该方法还包括在被鉴定为具有或具有心脏应激和/或骨骼肌应激风险的受试者中施用或进行适当的治疗。 本发明的另一方面涉及方法，系统和计算机可读介质检测Fst1表达水平，例如从相对于参考Fst1表达水平的低水平为低的受试者获得的生物样品中的Fstl1多肽或mRNA表达 指示患有或具有糖尿病和/或代谢功能障碍风险的受试者。 在这样的实施方案中，该方法还包括在被鉴定为具有或具有糖尿病和/或代谢功能障碍风险的受试者中施用或进行适当的治疗。

    Methods And Compositions Using Adiponectin For Treatment Of Cardiac Disorders And For Stimulation Of Angiogenesis
    10.
    发明申请
    Methods And Compositions Using Adiponectin For Treatment Of Cardiac Disorders And For Stimulation Of Angiogenesis 审中-公开
    使用脂联素治疗心脏疾病和刺激血管发生的方法和组合

    公开(公告)号：US20070213263A1

    公开(公告)日：2007-09-13

    申请号：US10574828

    申请日：2004-10-08

    申请人： Kenneth Walsh ,  Noriyuki Ouchi

    发明人： Kenneth Walsh ,  Noriyuki Ouchi

    IPC分类号： A61K38/17 ,  A61K48/00

    CPC分类号： A61K48/005 ,  A01K2267/0375 ,  A61K38/2264 ,  A61K48/00 ,  C12N2799/022 ,  C12N2799/04

    摘要： We have surprisingly discovered that adiponectin regulates angiogenesis and have shown that adiponectin is an effective agent at treating cardiac disorders. As a result of this discovery, the present invention provides methods for treatment of cardiac disorders and methods for stimulation of angiogenesis in tissues using adiponectin. In one preferred embodiment, the methods of the invention are used to treat complications of diabetes, such as ischemic limbs and hypertrophic cardiomyopathy.

    摘要翻译： 我们惊奇地发现脂联素调节血管发生，并且已经表明脂连蛋白是治疗心脏疾病的有效药物。 作为该发现的结果，本发明提供了治疗心脏疾病的方法和用脂联素刺激组织中血管发生的方法。 在一个优选实施方案中，本发明的方法用于治疗糖尿病的并发症，例如缺血性肢体和肥大型心肌病。